Sentence examples for premarket study from inspiring English sources

The purpose of this study was to ascertain the aneurysm-related mortality rate of a subgroup of the patient cohort from Medtronic's investigational premarket study.

However, if the immune response to the reference product is relatively rare, as in diabetes, two separate studies may be sufficient to evaluate immunogenicity a premarket study powered to detect major differences and a postmarket study to detect more subtle differences.

Other sources were whistleblowers, peer reviewers who drew attention to unpublished trials, and meta-analyses of unpublished trials, sometimes done by the manufacturers for example, pooling premarket studies to increase power.

Differences in manufacturing processes could lead to small differences in a biosimilar's overall efficacy and safety profile, including immunogenicity [ 2– 4], which may not be detected in the abbreviated clinical and non-clinical premarket studies required for regulatory approval of the biosimilar product [ 3, 5].

Under the law, device producers will have to report such "premarketing" studies and their results to the F.D.A.

Although most countries require similar types of premarketing studies to be completed, differences in specific regulations and guidelines exist.

Thus, if pharmaceutical firms wish to market their new drugs in many countries, they may face challenges created by the differing regulations and guidelines for premarketing studies.

Postmarketing safety surveillance can provide information based on real-world use of medical products in heterogeneous populations and is critical for identifying potentially serious adverse events, events that are too rare to be detected during premarketing studies, late complications, and events involving individuals or uses that were not evaluated in clinical trials.

The majority of DDI studies consist of case reports and premarketing studies evaluating nonclinical endpoints in healthy subjects.

SRSs are important for identification of safety signals, including potential rare AEs not identified during clinical trials or premarketing studies [ 10].

Trial summaries include premarketing studies that were sent to regulatory agencies for drug approval and postmarketing studies for new indications, additional outcomes and long-term follow-up.